---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000112"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:11:05.250898+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track

## Summary
- Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.
- Cash and securities $428.8M (down from $609.6M at Nov 2024); R&D spend $86.1M, up 55% YoY.
- Bexobrutideg ORR 80.9% in CLL (n=47) and 84.2% in WM (n=19); pivotal trials planned H2 2025.
- Preclinical data for GS-6791 (IRAK4 degrader with Gilead) presented at EADV; IND-enabling STAT6 degrader with Sanofi.
- Collaboration revenue declined as Sanofi initial research term ended; partially offset by Pfizer milestone completion.

## SEC filing metadata
- accession: 0001549595-25-000112
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/0001549595-25-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/nrix-20251009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000112
- JSON: https://secwatch.observer/filing/0001549595-25-000112.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.